Wall Street expects a year-over-year decline in earnings on lower revenues when Pfizer (PFE) reports results for the quarter ...

* Indicates calculation not meaningful or results are greater than 100%. First-quarter 2025 Cost of Sales (2) as a percentage of revenues decreased by 2.0 percentage points compared to the prior-year ...

Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc. recorded in the third quarter of 2025 with an unfavorable impact of ...

Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion that the pharmaceutical giant delayed announcing a successful Covid-19 ...

Second-quarter 2025 Cost of Sales(3) as a percentage of revenues increased by 0.9 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a favorable revision ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

$2.2 billion invested in internal research and development projects, and Approximately $90 million invested in business development transactions. Returning capital directly to shareholders through ...